Mathias Witzens‐Harig

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman et al. · The Lancet · 2015 · 462 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous Transplantation

Patrick Wuchter, Dan Ran, Thomas Brückner et al. · Biology of Blood and Marrow Transplantation · 2009 · 264 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 253 citations · Full text

Medicine, Oncology, Cancer Immunology +10

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

Andreas Trojan, Joachim L. Schultze, Mathias Witzens‐Harig et al. · Nature Medicine · 2000 · 175 citations

Life Sciences, Immunology, Molecular Biology +16